HISTONE DEACETYLASES AND CANCER: CAUSES AND THERAPIES
β Scribed by Marks, Paul A.; Rifkind, Richard A.; Richon, Victoria M.; Breslow, Ronald; Miller, Thomas; Kelly, William K.
- Book ID
- 109776742
- Publisher
- Nature Publishing Group
- Year
- 2001
- Tongue
- English
- Weight
- 623 KB
- Volume
- 1
- Category
- Article
- ISSN
- 1474-1776
- DOI
- 10.1038/35106079
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
## Abstract Histone deacetylase (HDAC) is recognized as one of the promising targets for cancer treatment as many HDAC inhibitors have entered clinical trials for both solid and liquid tumors. Nevertheless, the mechanisms underlying the antiproliferative effects of HDAC inhibitors remain elusive. A
A key event in the regulation of eukaryotic gene expression is the posttranslational modification of nucleosomal histones, which converts regions of chromosomes into transcriptionally active or inactive chromatin. The most well studied posttranslational modification of histones is the acetylation of